Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 268

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 268
---
 of 2020 Notes outstanding are as follows:

|                  |     |   | December 31, 
         2024 |   |     |   | December 31, 
         2023 |   |
|:-----------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |        1,350 |   |     | $ |          900 |   |
| Discount rate    |     |   |           30 | % |     |   |         30.0 | % |
| Term (years)     |     |   |         0.40 |   |     |   |         0.25 |   |
| Fair value       |     | $ |        4,372 |   |     | $ |        7,405 |   |

<div align='center'>F-17</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | CONVERTIBLE NOTES (Cont.) |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the fair value of the 2020 Notes by applying a +/- 5.0% changes to the discount rate used in PWERM.

As of December 31, 2024, a 5.0%
decrease in discount rate would increase the fair value of the 2020 Notes to $4,444; a 5.0% increase in discount rate would decrease
the fair value of the 2020 Notes to $4,305.

c. On March 11, 2023, the Company
converted the 2021 Notes into 88,385 preferred D-2 shares.

The following table presents changes
in the fair value of the 2020 Notes and 2021 Notes:

| Balance as of January 1, 2023                          |     | $ |  6,472 |   |
| Conversion of the 2021 Notes into preferred D-2 shares |     |   | (1,086 | ) |
| Changes in fair value                                  |     |   |  2,019 |   |
| Balance as of December 31, 2023                        |     | $ |